<drug type="biotech" created="2005-06-13" updated="2021-01-01">
  <drugbank-id primary="true">DB00028</drugbank-id>
  <drugbank-id>BTD00091</drugbank-id>
  <drugbank-id>BIOD00091</drugbank-id>
  <name>Human immunoglobulin G</name>
  <description>Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.</description>
  <cas-number>308067-58-5</cas-number>
  <unii>66Y330CJHS</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A36</ref-id>
        <pubmed-id>20970960</pubmed-id>
        <citation>Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1):9-15. doi: 10.1016/j.jaut.2010.09.006. Epub 2010 Dec  9.</citation>
      </article>
      <article>
        <ref-id>A37</ref-id>
        <pubmed-id>17911465</pubmed-id>
        <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
      </article>
      <article>
        <ref-id>A38</ref-id>
        <pubmed-id>16998749</pubmed-id>
        <citation>Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006 Sep;253 Suppl 5:V18-24.</citation>
      </article>
      <article>
        <ref-id>A39</ref-id>
        <pubmed-id>12032582</pubmed-id>
        <citation>Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Wolfgang Stephan, "Production of intravenously applicable native human immune globulin having a normal half-life." U.S. Patent US4082734, issued July, 1970.</synthesis-reference>
  <indication>IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases.</indication>
  <pharmacodynamics>Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.</pharmacodynamics>
  <mechanism-of-action>IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>&gt;20 hours (mammalian reticulocytes, in vitro).</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Human IGG</synonym>
    <synonym language="english" coder="">Human immunoglobulin G</synonym>
    <synonym language="english" coder="">Human normal immunoglobulin</synonym>
    <synonym language="english" coder="">Immune globulin (human)</synonym>
    <synonym language="english" coder="">Immune globulin human</synonym>
    <synonym language="english" coder="">Immunoglobulin (human)</synonym>
    <synonym language="english" coder="">Immunoglobulin G (human)</synonym>
    <synonym language="english" coder="">Immunoglobulin G, human</synonym>
    <synonym language="english" coder="">IVIg</synonym>
  </synonyms>
  <products>
    <product>
      <name>Asceniv</name>
      <labeller>Adma Biologics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69800-0250</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125590</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivigam</name>
      <labeller>Kedrion Biopharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76125-918</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 g/10mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivigam</name>
      <labeller>Adma Biologics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69800-6502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivigam</name>
      <labeller>Adma Biologics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69800-6503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-21</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivigam</name>
      <labeller>ADMA Biologics, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>59730-6502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-04</started-marketing-on>
      <ended-marketing-on>2021-09-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivigam</name>
      <labeller>ADMA Biologics, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>59730-6503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-04</started-marketing-on>
      <ended-marketing-on>2021-09-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Carimune Nanofiltered</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-416</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-06-07</started-marketing-on>
      <ended-marketing-on>2009-01-06</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>3 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102367</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Carimune Nanofiltered</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-417</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-10</started-marketing-on>
      <ended-marketing-on>2021-05-31</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>6 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102367</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Carimune Nanofiltered</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-418</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-10</started-marketing-on>
      <ended-marketing-on>2021-05-31</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>12 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102367</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Octapharma USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68982-810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>165 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125668</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1061</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>165 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125668</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1802</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>165 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125668</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>165 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125668</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1960</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>165 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125668</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1509</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>165 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125668</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1965</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>165 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125668</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02472996</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 g</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473003</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1.65 g</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473011</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 g</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473038</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>3.3 g</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473046</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4 g</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cutaquig</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473054</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>8 g</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cuvitru</name>
      <labeller>Baxalta Us Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2850</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125596</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cuvitru</name>
      <labeller>Shire Pharma Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02461692</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Flebogamma</name>
      <labeller>Grifols</labeller>
      <ndc-id/>
      <ndc-product-code>61953-0003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-15</started-marketing-on>
      <ended-marketing-on>2009-11-02</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.5 g/10mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flebogamma 10%</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02467526</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Flebogamma 5%</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02467488</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000781</ema-product-code>
      <ema-ma-number>EU/1/07/404/001</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000781</ema-product-code>
      <ema-ma-number>EU/1/07/404/002</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000781</ema-product-code>
      <ema-ma-number>EU/1/07/404/003</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000781</ema-product-code>
      <ema-ma-number>EU/1/07/404/004</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000781</ema-product-code>
      <ema-ma-number>EU/1/07/404/005</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000781</ema-product-code>
      <ema-ma-number>EU/1/07/404/006</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000781</ema-product-code>
      <ema-ma-number>EU/1/07/404/007</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>Instituto Grifols, S.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000781</ema-product-code>
      <ema-ma-number>EU/1/07/404/008</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Flebogamma DIF</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>61953-0004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.05 g/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>61953-0005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GamaSTAN</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13533-335</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.165 g/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA101134</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gamastan</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13533-635</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.165 g/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA101134</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gamastan</name>
      <labeller>Cutter Med &amp; Biol, Division Of Miles Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00083259</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>16.5 %</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamastan</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486598</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2020-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>18 %</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamastan S/d</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230579</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamimune N 10% (iv)</name>
      <labeller>Talecris Biotherapeutics Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229695</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-05-16</started-marketing-on>
      <ended-marketing-on>2006-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamimune N 5% (iv)</name>
      <labeller>Talecris Biotherapeutics Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02178842</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-01-17</started-marketing-on>
      <ended-marketing-on>2006-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamimune N Inj 5% (iv)</name>
      <labeller>Cutter Med &amp; Biol, Division Of Miles Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00559261</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>GAMMAGARD Liquid</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA125105</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GAMMAGARD Liquid</name>
      <labeller>Shire Pharma Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279444</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 %</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231471</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231470</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2656</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2658</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2623</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on>2014-06-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on>2014-06-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2627</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on>2014-06-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2620</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on>2015-09-02</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2655</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-03</started-marketing-on>
      <ended-marketing-on>2015-08-26</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231469</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-22</started-marketing-on>
      <ended-marketing-on>2015-05-12</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2.5 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammagard S/d (iv)</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231468</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-22</started-marketing-on>
      <ended-marketing-on>2013-11-04</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammaked</name>
      <labeller>Kedrion Biopharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76125-900</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA125046</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammaplex</name>
      <labeller>Bio Products Laboratory Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64208-8234</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125329</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammaplex</name>
      <labeller>Bio Products Laboratory Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64208-8235</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125329</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammar Inj 165mg/ml</name>
      <labeller>Armour Pharmaceutical Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01915312</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>1999-12-15</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamunex</name>
      <labeller>Grifols</labeller>
      <ndc-id/>
      <ndc-product-code>13533-645</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-27</started-marketing-on>
      <ended-marketing-on>2013-10-22</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>1 g/1g</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125046</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gamunex</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247724</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 g</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamunex-C</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13533-800</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA125046</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/001</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/002</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/003</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/004</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/005</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/006</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/010</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/011</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/012</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/013</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/014</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-451</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.2 g/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-452</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.2 g/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-454</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.2 g/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-455</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.2 g/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-456</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2020-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.2 g/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-457</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2020-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.2 g/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-458</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2020-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>0.2 g/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/015</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/016</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/017</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/018</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/019</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002127</ema-product-code>
      <ema-ma-number>EU/1/11/687/020</ema-ma-number>
      <started-marketing-on>2011-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02370352</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02463059</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02463067</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02498251</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hyperrho S/d Full Dose</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243524</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1500 unit</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hyperrho S/d Full Dose</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02379457</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1500 unit</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta Innovations Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002491</ema-product-code>
      <ema-ma-number>EU/1/13/840/001</ema-ma-number>
      <started-marketing-on>2013-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta Innovations Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002491</ema-product-code>
      <ema-ma-number>EU/1/13/840/002</ema-ma-number>
      <started-marketing-on>2013-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta Innovations Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002491</ema-product-code>
      <ema-ma-number>EU/1/13/840/003</ema-ma-number>
      <started-marketing-on>2013-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta Innovations Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002491</ema-product-code>
      <ema-ma-number>EU/1/13/840/004</ema-ma-number>
      <started-marketing-on>2013-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta Innovations Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002491</ema-product-code>
      <ema-ma-number>EU/1/13/840/005</ema-ma-number>
      <started-marketing-on>2013-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta US Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Igivnex</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277921</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Immune Globulin Intravenous (human) 5%</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02185342</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Immune Globulin Intravenous (human), 10%</name>
      <labeller>Talecris Biotherapeutics Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230920</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-07-31</started-marketing-on>
      <ended-marketing-on>2006-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Immune Globulin Intravenous (human), 5%</name>
      <labeller>Talecris Biotherapeutics Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230919</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-11-03</started-marketing-on>
      <ended-marketing-on>2006-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Immune Serum Globulin (human)</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230647</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Iveegam Immuno 5000mg (iv)</name>
      <labeller>Baxter Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959301</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2008-12-23</ended-marketing-on>
      <dosage-form>Kit; Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kiovig</name>
      <labeller>Baxter Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000628</ema-product-code>
      <ema-ma-number>EU/1/05/329/001</ema-ma-number>
      <started-marketing-on>2006-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kiovig</name>
      <labeller>Baxter Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000628</ema-product-code>
      <ema-ma-number>EU/1/05/329/002</ema-ma-number>
      <started-marketing-on>2006-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kiovig</name>
      <labeller>Baxter Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000628</ema-product-code>
      <ema-ma-number>EU/1/05/329/003</ema-ma-number>
      <started-marketing-on>2006-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kiovig</name>
      <labeller>Baxter Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000628</ema-product-code>
      <ema-ma-number>EU/1/05/329/004</ema-ma-number>
      <started-marketing-on>2006-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kiovig</name>
      <labeller>Baxter Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000628</ema-product-code>
      <ema-ma-number>EU/1/05/329/005</ema-ma-number>
      <started-marketing-on>2006-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kiovig</name>
      <labeller>Baxter Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000628</ema-product-code>
      <ema-ma-number>EU/1/05/329/006</ema-ma-number>
      <started-marketing-on>2006-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Octagam 10%</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02380145</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Octagam 5%</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02267713</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Octagam Immune Globulin (Human)</name>
      <labeller>Octapharma Pharmazeutika Produktionsgesellschaft M.B.H.</labeller>
      <ndc-id/>
      <ndc-product-code>67467-843</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125062</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octagam Immune Globulin (Human)</name>
      <labeller>Octapharma Ab</labeller>
      <ndc-id/>
      <ndc-product-code>68209-843</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125062</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octagam Immune Globulin (Human)</name>
      <labeller>Octapharma USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68982-850</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125062</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octagam Immune Globulin (Human)</name>
      <labeller>Octapharma USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68982-840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125062</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panzyga</name>
      <labeller>Octapharma USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68982-820</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panzyga</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panzyga</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panzyga</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1224</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panzyga</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panzyga</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1415</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panzyga</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1558</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panzyga</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456087</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000831</ema-product-code>
      <ema-ma-number>EU/1/08/446/001</ema-ma-number>
      <started-marketing-on>2008-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000831</ema-product-code>
      <ema-ma-number>EU/1/08/446/002</ema-ma-number>
      <started-marketing-on>2008-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000831</ema-product-code>
      <ema-ma-number>EU/1/08/446/003</ema-ma-number>
      <started-marketing-on>2008-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000831</ema-product-code>
      <ema-ma-number>EU/1/08/446/004</ema-ma-number>
      <started-marketing-on>2008-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000831</ema-product-code>
      <ema-ma-number>EU/1/08/446/005</ema-ma-number>
      <started-marketing-on>2008-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000831</ema-product-code>
      <ema-ma-number>EU/1/08/446/006</ema-ma-number>
      <started-marketing-on>2008-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000831</ema-product-code>
      <ema-ma-number>EU/1/08/446/007</ema-ma-number>
      <started-marketing-on>2008-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-437</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-438</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>20 g/200mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>40 g/400mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02304619</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 %</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoglobulin Nf Liquid</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02287994</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-28</started-marketing-on>
      <ended-marketing-on>2010-04-20</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vivaglobin</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-7596</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-01-09</started-marketing-on>
      <ended-marketing-on>2013-09-07</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>160 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125115</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vivaglobin</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282518</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on>2015-04-02</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>160 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene BioPharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-03-31</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>600 [iU]/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene BioPharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-03-31</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>2500 [iU]/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene BioPharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-31</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>5000 [iU]/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene BioPharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-03-31</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>15000 [iU]/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene BioPharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-03-31</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>1500 [iU]/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xembify</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13533-810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125683</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xembify</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02494426</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 %</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Octagam Immune Globulin (Human)</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Octagam Immune Globulin (Human)</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamunex</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Vivaglobin</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Bivigam</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Carimune Nanofiltered</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Panzyga</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Asceniv</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Octagam Immune Globulin (Human)</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>GAMMAGARD Liquid</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cuvitru</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Bivigam</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Bivigam</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Panzyga</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Panzyga</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Panzyga</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Panzyga</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Panzyga</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Panzyga</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Octagam Immune Globulin (Human)</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Xembify</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma DIF</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Bivigam</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Bivigam</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammaked</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamunex-C</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>GamaSTAN</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamastan</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Carimune Nanofiltered</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Carimune Nanofiltered</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G + Hyaluronidase (human recombinant)</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G + Hyaluronidase (human recombinant)</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G + Hyaluronidase (human recombinant)</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G + Hyaluronidase (human recombinant)</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Human immunoglobulin G + Hyaluronidase (human recombinant)</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammaplex</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammaplex</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamastan S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamunex</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Igivnex</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Octagam 10%</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammar Inj 165mg/ml</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Iveegam Immuno 5000mg (iv)</name>
      <ingredients>Human immunoglobulin G + Water</ingredients>
    </mixture>
    <mixture>
      <name>Immune Globulin Intravenous (human) 5%</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamimune N 5% (iv)</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamastan</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamimune N 10% (iv)</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Immune Globulin Intravenous (human), 5%</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Immune Globulin Intravenous (human), 10%</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d (iv)</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamimune N Inj 5% (iv)</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Vivaglobin</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Sandoglobulin Nf Liquid</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hyperrho S/d Full Dose</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Octagam 5%</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hyperrho S/d Full Dose</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Panzyga</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma 5%</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma 10%</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Immune Serum Globulin (human)</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cutaquig</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>GAMMAGARD Liquid</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Cuvitru</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Gamastan</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Xembify</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Human immunoglobulin G</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Alpha Therapeutic Corp.</name>
      <url/>
    </packager>
    <packager>
      <name>American Red Cross</name>
      <url>http://www.redcross.org</url>
    </packager>
    <packager>
      <name>Baxter International Inc.</name>
      <url>http://www.baxter.com</url>
    </packager>
    <packager>
      <name>Biotest Pharmaceuticals</name>
      <url>http://www.biotestpharma.com</url>
    </packager>
    <packager>
      <name>Cangene Corp.</name>
      <url>http://www.cangene.com</url>
    </packager>
    <packager>
      <name>CSL Behring LLC</name>
      <url>http://www.cslbehring.com</url>
    </packager>
    <packager>
      <name>Grifols SA</name>
      <url>http://www.grifols.com</url>
    </packager>
    <packager>
      <name>Massachusetts Public Health</name>
      <url>http://www.mphaweb.org</url>
    </packager>
    <packager>
      <name>Massbiologics</name>
      <url>http://www.massbio.org</url>
    </packager>
    <packager>
      <name>Medimmune Inc.</name>
      <url>http://www.medimmune.com</url>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
    <packager>
      <name>Octapharma USA</name>
      <url>http://www.octapharma.com</url>
    </packager>
    <packager>
      <name>Talecris Biotherapeutics</name>
      <url>http://www.talecris.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Flebogamma 5% vial</description>
      <cost currency="USD">4.84</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Flebogamma dif 5% vial</description>
      <cost currency="USD">4.84</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Immune globulin vial</description>
      <cost currency="USD">9.34</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Gamunex 10% vial</description>
      <cost currency="USD">11.6</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Gammagard liquid 10% vial</description>
      <cost currency="USD">13.79</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Gamastan s-d vial</description>
      <cost currency="USD">24.44</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hizentra 1 gram/5 ml vial</description>
      <cost currency="USD">30.24</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hizentra 2 gram/10 ml vial</description>
      <cost currency="USD">30.24</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hizentra 4 gram/20 ml vial</description>
      <cost currency="USD">30.24</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hyperhep b s-d vial</description>
      <cost currency="USD">165.04</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Nabi-hb vial</description>
      <cost currency="USD">176.34</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hyperrab s-d vial</description>
      <cost currency="USD">224.07</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hypertet s-d 250 unit syringe</description>
      <cost currency="USD">324.23</cost>
      <unit>syringe</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Antigen Neutralization</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Human Immunoglobulin G</category>
      <mesh-id/>
    </category>
    <category>
      <category>Immunoglobulin G</category>
      <mesh-id>D007074</mesh-id>
    </category>
    <category>
      <category>Immunoglobulin Isotypes</category>
      <mesh-id>D007132</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins, Intravenous</category>
      <mesh-id>D016756</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Passively Acquired Immunity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serum</category>
      <mesh-id>D044967</mesh-id>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
    <affected-organism>Bacteria and protozoa</affected-organism>
    <affected-organism>Various viruses</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>5 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>160 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>800 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>160 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>1 g/10mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>10 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>10 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>12 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>3 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>6 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>165 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>1.65 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>165 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>2 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>3.3 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>8 g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>165 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>200 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>200 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Parenteral</route>
      <strength>50 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>0.5 g/10mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>5 %</strength>
    </dosage>
    <dosage>
      <form>Solution, concentrate</form>
      <route>Intravenous</route>
      <strength>10 g</strength>
    </dosage>
    <dosage>
      <form>Solution, concentrate</form>
      <route>Intravenous</route>
      <strength>20 g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>0.05 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>100 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>5 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>50 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Solution, concentrate</form>
      <route>Intravenous</route>
      <strength>5 g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>0.165 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular</route>
      <strength>16.5 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength>18 %</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>1.65 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>50 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>10 g</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>2.5 g</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>5 g</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>50 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>2.5 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>165 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>5 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>5 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Parenteral</route>
      <strength>100 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 g</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>0.1 g/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>10 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>20 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>5 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Parenteral</route>
      <strength>10 %</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>2.5 g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>2.5 g/25mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>10 g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>20 g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>5 g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 %</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>5 g/100ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>4 g/20mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>200 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Subcutaneous</route>
      <strength>0.2 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>4 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>1 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength>1500 unit</strength>
    </dosage>
    <dosage>
      <form/>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>100 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>100 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>50 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>1 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>10 gr/200ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>1 g/20ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>2.5 g/50ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>5 gr/100ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Parenteral</route>
      <strength>50 g/l</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>50 mg (titer)</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>5 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Parenteral</route>
      <strength>160 mg</strength>
    </dosage>
    <dosage>
      <form>Solution, concentrate</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>6 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>3 g/50ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>100 G/L</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>50 G/L</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>10 g/200ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Parenteral</route>
      <strength>100 g/l</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>100 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Kit; liquid; powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>1000 UI/3ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>180 UI/1ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>540 UI/3ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>160 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 gr/100ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>100 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>2.5 gr/25ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>20 gr/200ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>30 gr/300ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>5 gr/50ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>160 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>100 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>5 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>50 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>1000 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>165 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Parenteral</route>
      <strength>70 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>100 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>50 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>20 g/200mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>40 g/400mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravascular</route>
      <strength>10 g/100ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravascular</route>
      <strength>2.5 g/25ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravascular</route>
      <strength>5 g/50ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>10 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>2.5 g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>5 %</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>10 g/200ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>5 g/100ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>5 g</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>160 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>160 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>160 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1500 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>15000 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>2500 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>5000 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>600 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>20 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>200 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>80:04.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Diethylstilbestrol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>Chlorotrianisene may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Conjugated estrogens may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>Estrone may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Estradiol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00890</drugbank-id>
      <name>Dienestrol</name>
      <description>Dienestrol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>Mestranol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>Estriol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Estrone sulfate may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>Hexestrol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Esterified estrogens</name>
      <description>Esterified estrogens may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>Equol</name>
      <description>Equol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>Methallenestril may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13386</drugbank-id>
      <name>Epimestrol</name>
      <description>Epimestrol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13418</drugbank-id>
      <name>Moxestrol</name>
      <description>Moxestrol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Estradiol acetate may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>Estradiol benzoate may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15334</drugbank-id>
      <name>Biochanin A</name>
      <description>Biochanin A may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15335</drugbank-id>
      <name>Formononetin</name>
      <description>Formononetin may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00002</drugbank-id>
      <name>Cetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Cetuximab is combined with Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00043</drugbank-id>
      <name>Omalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Omalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00057</drugbank-id>
      <name>Indium In-111 satumomab pendetide</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indium In-111 satumomab pendetide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Basiliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Muromonab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00076</drugbank-id>
      <name>Digoxin Immune Fab (Ovine)</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Digoxin Immune Fab (Ovine).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alemtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00089</drugbank-id>
      <name>Capromab pendetide</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Capromab pendetide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Efalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antithymocyte immunoglobulin (rabbit).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00110</drugbank-id>
      <name>Palivizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Palivizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00113</drugbank-id>
      <name>Technetium Tc-99m arcitumomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Technetium Tc-99m arcitumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eculizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01269</drugbank-id>
      <name>Panitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Panitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01270</drugbank-id>
      <name>Ranibizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ranibizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04901</drugbank-id>
      <name>Galiximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Galiximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04949</drugbank-id>
      <name>Pexelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pexelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04958</drugbank-id>
      <name>Epratuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Epratuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04962</drugbank-id>
      <name>Bectumomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bectumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04964</drugbank-id>
      <name>Oregovomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04988</drugbank-id>
      <name>IGN311</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IGN311.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05006</drugbank-id>
      <name>Adecatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adecatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05097</drugbank-id>
      <name>Labetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Labetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05101</drugbank-id>
      <name>Matuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Matuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05111</drugbank-id>
      <name>Fontolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fontolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05136</drugbank-id>
      <name>Bavituximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bavituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05139</drugbank-id>
      <name>CR002</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with CR002.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05209</drugbank-id>
      <name>Rozrolimupab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rozrolimupab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05304</drugbank-id>
      <name>Girentuximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Girentuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05336</drugbank-id>
      <name>Obiltoxaximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Obiltoxaximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05405</drugbank-id>
      <name>XTL-001</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with XTL-001.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05437</drugbank-id>
      <name>NAV 1800</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with NAV 1800.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Briakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05496</drugbank-id>
      <name>Otelixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Otelixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05545</drugbank-id>
      <name>AMG 108</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with AMG 108.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05550</drugbank-id>
      <name>Iratumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Iratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05555</drugbank-id>
      <name>Enokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Enokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05578</drugbank-id>
      <name>Ramucirumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ramucirumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05595</drugbank-id>
      <name>Farletuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Farletuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05656</drugbank-id>
      <name>Veltuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Veltuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05679</drugbank-id>
      <name>Ustekinumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ustekinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05793</drugbank-id>
      <name>PRO-542</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with PRO-542.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05797</drugbank-id>
      <name>TNX-901</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with TNX-901.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inotuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05892</drugbank-id>
      <name>RI 624</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with RI 624.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05915</drugbank-id>
      <name>MYO-029</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with MYO-029.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05916</drugbank-id>
      <name>CT-011</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with CT-011.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05941</drugbank-id>
      <name>Leronlimab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Leronlimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05996</drugbank-id>
      <name>Glembatumumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Glembatumumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06043</drugbank-id>
      <name>Olaratumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Olaratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06049</drugbank-id>
      <name>IPH 2101</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IPH 2101.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06050</drugbank-id>
      <name>TB-402</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with TB-402.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Caplacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06101</drugbank-id>
      <name>IMC-1C11</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IMC-1C11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06116</drugbank-id>
      <name>Eldelumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eldelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06162</drugbank-id>
      <name>Lumiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lumiliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ipilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06192</drugbank-id>
      <name>Nimotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nimotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06241</drugbank-id>
      <name>Clenoliximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Clenoliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06304</drugbank-id>
      <name>BIIB015</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with BIIB015.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06305</drugbank-id>
      <name>Sonepcizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sonepcizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06310</drugbank-id>
      <name>Motavizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Motavizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06317</drugbank-id>
      <name>Elotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Elotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06318</drugbank-id>
      <name>AVE9633</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with AVE9633.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06322</drugbank-id>
      <name>Carotuximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Carotuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06324</drugbank-id>
      <name>XmAb 2513</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with XmAb 2513.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06342</drugbank-id>
      <name>Coltuximab ravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Coltuximab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06343</drugbank-id>
      <name>Teprotumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Teprotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06360</drugbank-id>
      <name>Lucatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lucatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06366</drugbank-id>
      <name>Pertuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pertuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06371</drugbank-id>
      <name>Siplizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Siplizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06467</drugbank-id>
      <name>Apolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Apolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06474</drugbank-id>
      <name>Sibrotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sibrotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06550</drugbank-id>
      <name>Bivatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bivatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06557</drugbank-id>
      <name>Lerdelimumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lerdelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06599</drugbank-id>
      <name>Lexatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lexatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06602</drugbank-id>
      <name>Reslizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Reslizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06606</drugbank-id>
      <name>Teplizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Teplizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06607</drugbank-id>
      <name>Catumaxomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Catumaxomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mepolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Denosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06647</drugbank-id>
      <name>Volociximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Volociximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06650</drugbank-id>
      <name>Ofatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ofatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08902</drugbank-id>
      <name>Raxibacumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Raxibacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09035</drugbank-id>
      <name>Nivolumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nivolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09037</drugbank-id>
      <name>Pembrolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pembrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dulaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anthrax immune globulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09105</drugbank-id>
      <name>Asfotase alfa</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Asfotase alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Idarucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09302</drugbank-id>
      <name>Alirocumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alirocumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09303</drugbank-id>
      <name>Evolocumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Evolocumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antilymphocyte immunoglobulin (horse).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09331</drugbank-id>
      <name>Daratumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09559</drugbank-id>
      <name>Necitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ixekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ravulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11595</drugbank-id>
      <name>Atezolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Atezolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11604</drugbank-id>
      <name>Tetanus Immune Globulin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tetanus Immune Globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11608</drugbank-id>
      <name>Eftrenonacog alfa</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eftrenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11621</drugbank-id>
      <name>Human Varicella-Zoster Immune Globulin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Human Varicella-Zoster Immune Globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11646</drugbank-id>
      <name>Conatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Conatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11657</drugbank-id>
      <name>Tabalumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tabalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11680</drugbank-id>
      <name>Ficlatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ficlatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11685</drugbank-id>
      <name>Figitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Figitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11714</drugbank-id>
      <name>Durvalumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Durvalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11715</drugbank-id>
      <name>Bapineuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bapineuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11731</drugbank-id>
      <name>Depatuxizumab mafodotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Depatuxizumab mafodotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11746</drugbank-id>
      <name>Onartuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Onartuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11756</drugbank-id>
      <name>Solanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Solanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11771</drugbank-id>
      <name>Tremelimumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tremelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brodalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sirukumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11826</drugbank-id>
      <name>Lampalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lampalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Guselkumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11840</drugbank-id>
      <name>Dalotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dalotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11849</drugbank-id>
      <name>Emibetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emibetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11850</drugbank-id>
      <name>Ublituximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ublituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11856</drugbank-id>
      <name>Ligelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ligelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11857</drugbank-id>
      <name>Seribantumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Seribantumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11862</drugbank-id>
      <name>Landogrozumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Landogrozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11866</drugbank-id>
      <name>Romosozumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Romosozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11884</drugbank-id>
      <name>Vadastuximab Talirine</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vadastuximab Talirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11914</drugbank-id>
      <name>Lebrikizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lebrikizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11930</drugbank-id>
      <name>Varlilumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Varlilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11945</drugbank-id>
      <name>Avelumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Avelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11959</drugbank-id>
      <name>Crenezumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Crenezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11972</drugbank-id>
      <name>Rilotumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rilotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11976</drugbank-id>
      <name>Anifrolumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anifrolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ocrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12023</drugbank-id>
      <name>Benralizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Benralizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12034</drugbank-id>
      <name>Gantenerumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gantenerumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12053</drugbank-id>
      <name>Visilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Visilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12077</drugbank-id>
      <name>Urelumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Urelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lorvotuzumab mertansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12090</drugbank-id>
      <name>Patritumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Patritumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12102</drugbank-id>
      <name>Fulranumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fulranumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12104</drugbank-id>
      <name>Tarextumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tarextumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12118</drugbank-id>
      <name>Sotatercept</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sotatercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12119</drugbank-id>
      <name>Gevokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gevokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12142</drugbank-id>
      <name>Duligotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Duligotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12152</drugbank-id>
      <name>Simtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Simtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12157</drugbank-id>
      <name>Fasinumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fasinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12159</drugbank-id>
      <name>Dupilumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dupilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12169</drugbank-id>
      <name>Tralokinumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tralokinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12189</drugbank-id>
      <name>Etrolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Etrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12202</drugbank-id>
      <name>Zalutumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zalutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12205</drugbank-id>
      <name>Ganitumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ganitumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12213</drugbank-id>
      <name>Etaracizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Etaracizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12240</drugbank-id>
      <name>Polatuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Polatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12246</drugbank-id>
      <name>Inclacumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inclacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12250</drugbank-id>
      <name>Cixutumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cixutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12261</drugbank-id>
      <name>Ascrinvacumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ascrinvacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12274</drugbank-id>
      <name>Aducanumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Aducanumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12281</drugbank-id>
      <name>Luspatercept</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Luspatercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12296</drugbank-id>
      <name>GS-5745</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with GS-5745.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12317</drugbank-id>
      <name>Vanucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vanucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12331</drugbank-id>
      <name>Labetuzumab govitecan</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Labetuzumab govitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12335</drugbank-id>
      <name>Tanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12342</drugbank-id>
      <name>Ensituximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ensituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12344</drugbank-id>
      <name>Fezakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fezakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12363</drugbank-id>
      <name>Dusigitumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dusigitumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12396</drugbank-id>
      <name>Fresolimumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fresolimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12413</drugbank-id>
      <name>Indusatumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indusatumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12456</drugbank-id>
      <name>Bococizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bococizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12489</drugbank-id>
      <name>Mirvetuximab Soravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mirvetuximab Soravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12498</drugbank-id>
      <name>Mogamulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mogamulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12520</drugbank-id>
      <name>Plozalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Plozalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12530</drugbank-id>
      <name>Inebilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inebilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12534</drugbank-id>
      <name>Mavrilimumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mavrilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12560</drugbank-id>
      <name>Blosozumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Blosozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12584</drugbank-id>
      <name>Bimagrumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bimagrumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12589</drugbank-id>
      <name>Dacetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dacetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12609</drugbank-id>
      <name>Tovetumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tovetumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12683</drugbank-id>
      <name>Lumretuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lumretuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12698</drugbank-id>
      <name>Ibalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12701</drugbank-id>
      <name>Intetumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Intetumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12718</drugbank-id>
      <name>Carlumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Carlumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12734</drugbank-id>
      <name>Demcizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Demcizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12773</drugbank-id>
      <name>Sifalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sifalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12775</drugbank-id>
      <name>Abituzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Abituzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12797</drugbank-id>
      <name>Ecromeximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ecromeximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12807</drugbank-id>
      <name>Naptumomab Estafenatox</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Naptumomab Estafenatox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12815</drugbank-id>
      <name>Crotedumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Crotedumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12820</drugbank-id>
      <name>Concizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Concizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12826</drugbank-id>
      <name>Depatuxizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Depatuxizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12844</drugbank-id>
      <name>Rontalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rontalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12845</drugbank-id>
      <name>Amatuximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Amatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12849</drugbank-id>
      <name>Clazakizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Clazakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12891</drugbank-id>
      <name>Ozanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ozanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12893</drugbank-id>
      <name>Sacituzumab govitecan</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sacituzumab govitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12917</drugbank-id>
      <name>Bimekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bimekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12943</drugbank-id>
      <name>Milatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Milatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12976</drugbank-id>
      <name>Robatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Robatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13017</drugbank-id>
      <name>Rovalpituzumab Tesirine</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rovalpituzumab Tesirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13037</drugbank-id>
      <name>Namilumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Namilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13045</drugbank-id>
      <name>Racotumomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Racotumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13073</drugbank-id>
      <name>Tregalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tregalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13127</drugbank-id>
      <name>Olokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Olokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13140</drugbank-id>
      <name>Bezlotoxumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bezlotoxumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13375</drugbank-id>
      <name>Edrecolomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Edrecolomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13535</drugbank-id>
      <name>Nebacumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nebacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13886</drugbank-id>
      <name>Human cytomegalovirus immune globulin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Human cytomegalovirus immune globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emicizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13976</drugbank-id>
      <name>Sulesomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sulesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13979</drugbank-id>
      <name>Besilesomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Besilesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14004</drugbank-id>
      <name>Tildrakizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14012</drugbank-id>
      <name>Burosumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Burosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14039</drugbank-id>
      <name>Erenumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Erenumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14040</drugbank-id>
      <name>Eptinezumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eptinezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14041</drugbank-id>
      <name>Fremanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fremanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14042</drugbank-id>
      <name>Galcanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Galcanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14211</drugbank-id>
      <name>Fanolesomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fanolesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14580</drugbank-id>
      <name>Lecanemab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lecanemab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14597</drugbank-id>
      <name>Lanadelumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lanadelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14707</drugbank-id>
      <name>Cemiplimab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cemiplimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14776</drugbank-id>
      <name>Camrelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Camrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14778</drugbank-id>
      <name>Setrusumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Setrusumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14784</drugbank-id>
      <name>Gancotamab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gancotamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14809</drugbank-id>
      <name>Anetumab ravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anetumab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14811</drugbank-id>
      <name>Isatuximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Isatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14824</drugbank-id>
      <name>Icrucumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Icrucumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14843</drugbank-id>
      <name>Codrituzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Codrituzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14864</drugbank-id>
      <name>Brolucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brolucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14871</drugbank-id>
      <name>Xentuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Xentuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14877</drugbank-id>
      <name>Lintuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lintuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14891</drugbank-id>
      <name>Vobarilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vobarilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14897</drugbank-id>
      <name>Parsatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Parsatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14905</drugbank-id>
      <name>Emactuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emactuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14907</drugbank-id>
      <name>Bevacizumab zirconium Zr-89</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab zirconium Zr-89.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14908</drugbank-id>
      <name>Refanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Refanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14947</drugbank-id>
      <name>Bermekimab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bermekimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14952</drugbank-id>
      <name>Pamrevlumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pamrevlumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14959</drugbank-id>
      <name>Opicinumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Opicinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab deruxtecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14967</drugbank-id>
      <name>Margetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Margetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14988</drugbank-id>
      <name>Dalantercept</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dalantercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14997</drugbank-id>
      <name>Pateclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pateclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15014</drugbank-id>
      <name>Gremubamab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gremubamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15022</drugbank-id>
      <name>Apomab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Apomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15044</drugbank-id>
      <name>Tafasitamab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tafasitamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15045</drugbank-id>
      <name>Ipafricept</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ipafricept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15076</drugbank-id>
      <name>Abrilumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Abrilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15089</drugbank-id>
      <name>Frovocimab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Frovocimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15090</drugbank-id>
      <name>Tezepelumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tezepelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15101</drugbank-id>
      <name>Tigatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tigatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15104</drugbank-id>
      <name>Telisotuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Telisotuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15113</drugbank-id>
      <name>Utomilumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Utomilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15118</drugbank-id>
      <name>Zolbetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zolbetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15135</drugbank-id>
      <name>Ponezumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ponezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15160</drugbank-id>
      <name>Asunercept</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Asunercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15172</drugbank-id>
      <name>Suvratoxumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Suvratoxumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15225</drugbank-id>
      <name>Mitazalimab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mitazalimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15252</drugbank-id>
      <name>Nemolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nemolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15277</drugbank-id>
      <name>Gedivumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gedivumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15336</drugbank-id>
      <name>Valanafusp alfa</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Valanafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15349</drugbank-id>
      <name>Sofituzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sofituzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15354</drugbank-id>
      <name>Evinacumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Evinacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15363</drugbank-id>
      <name>Istiratumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Istiratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15383</drugbank-id>
      <name>Pidilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pidilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15397</drugbank-id>
      <name>GMA-161</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with GMA-161.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15409</drugbank-id>
      <name>Ladiratuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ladiratuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15415</drugbank-id>
      <name>Tomaralimab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tomaralimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15428</drugbank-id>
      <name>Vesencumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vesencumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15432</drugbank-id>
      <name>Pinatuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pinatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15441</drugbank-id>
      <name>Lulizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lulizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15443</drugbank-id>
      <name>Lorukafusp alfa</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lorukafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15453</drugbank-id>
      <name>Naratuximab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Naratuximab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15559</drugbank-id>
      <name>Zenocutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zenocutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15898</drugbank-id>
      <name>Atoltivimab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Atoltivimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15899</drugbank-id>
      <name>Maftivimab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Maftivimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15900</drugbank-id>
      <name>Odesivimab</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Odesivimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15719</drugbank-id>
      <name>Belantamab mafodotin</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Belantamab mafodotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15595</drugbank-id>
      <name>Ebola Zaire vaccine (live, attenuated)</name>
      <description>The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15258</drugbank-id>
      <name>Imlifidase</name>
      <description>The therapeutic efficacy of Imlifidase can be decreased when used in combination with Human immunoglobulin G.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;IGG1
PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGV
PDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVT
LFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASS
YLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTV
SGDSINTILYYWSWIRQPPGKGLEWIGYIYYSGSTYGNPSLKSRVTISVNTSKNQFYSKL
SSVTAADTAVYYCARVPLVVNPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPQPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KPSNTKVDKRVAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYV
DGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL</sequence>
    <sequence format="FASTA">&gt;IgA2
ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPS
RFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKAS
GYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSS
LRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSSASPTSPKVFPLSLDSTPQDGNVVV
ACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVT
CHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASG
ATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTA
NITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYL
TWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPT
HVNVSVVMAEVDGTCY</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
      <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.331</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.13</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>142682.3</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C6332H9826N1692O1980S42</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7773</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>15161</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22953</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508774</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00221</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164754884</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01877</identifier>
    </external-identifier>
    <external-identifier>
      <resource>RxCUI</resource>
      <identifier>1426680</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/baygam.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/immune-globulin-human.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000710</id>
      <name>High affinity immunoglobulin gamma Fc receptor I</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P12314" source="Swiss-Prot">
        <name>High affinity immunoglobulin gamma Fc receptor I</name>
        <general-function>Receptor signaling protein activity</general-function>
        <specific-function>High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.</specific-function>
        <gene-name>FCGR1A</gene-name>
        <locus>1q21.2-q21.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>293-313</transmembrane-regions>
        <signal-regions>1-15</signal-regions>
        <theoretical-pi>8.08</theoretical-pi>
        <molecular-weight>42631.525</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3613</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FCGR1A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X14356</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31332</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P12314</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FCGR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Fc-gamma RI</synonym>
          <synonym>Fc-gamma RIA</synonym>
          <synonym>FCG1</synonym>
          <synonym>FcgammaRIa</synonym>
          <synonym>FCGR1</synonym>
          <synonym>FcRI</synonym>
          <synonym>IGFR1</synonym>
          <synonym>IgG Fc receptor I</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I
MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
LQEGVHRKEPQGAT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)
ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
AAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC
CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00047</identifier>
            <name>ig</name>
          </pfam>
          <pfam>
            <identifier>PF13895</identifier>
            <name>Ig_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>clathrin-coated endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>early endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor signaling protein activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antigen processing and presentation of exogenous peptide antigen via MHC class I</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antigen processing and presentation of peptide antigen via MHC class I</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interferon-gamma-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phagocytosis, engulfment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0004684</id>
      <name>High affinity immunoglobulin gamma Fc receptor IB</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q92637" source="Swiss-Prot">
        <name>High affinity immunoglobulin gamma Fc receptor IB</name>
        <general-function>Immunoglobulin receptor activity</general-function>
        <specific-function>May bind to the Fc region of immunoglobulins gamma with a low affinity compared to FCGR1A. May function in the humoral immune response.</specific-function>
        <gene-name>FCGR1B</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>199-219</transmembrane-regions>
        <signal-regions>1-15</signal-regions>
        <theoretical-pi/>
        <molecular-weight>32231.795</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3614</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q92637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FCGRB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Fc-gamma RIB</synonym>
          <synonym>FcRIB</synonym>
          <synonym>hFcgammaRIB</synonym>
          <synonym>IGFRB</synonym>
          <synonym>IgG Fc receptor IB</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009601|High affinity immunoglobulin gamma Fc receptor IB
MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFMEGEPL
ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
ISQYTVKGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWNLEISLDSGHE
KKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGAT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020794|High affinity immunoglobulin gamma Fc receptor IB (FCGR1B)
ATGTGGTTCTTGACAACTCTGCTCCTTTGGGGCTGGCTACTACTGCAGGTCTCCAGCAGA
GTCTTCATGGAAGGAGAACCTCTGGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTG
TACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAAC
CTCACCATTCTGAAAACCAACATAAGTCACAATGGCACCTACCATTGCTCAGGCATGGGA
AAGCATCGCTACACATCAGCAGGAATATCACAATACACTGTGAAAGGCCTCCAGTTACCA
ACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGAATAATGTTTTTAGTGAAC
ACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAGAAAAAGTGGAATTTAGAA
ATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGCCTTCAAGAAGACAGACAT
TTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAGCTGCAGGAAGGGGTGCAC
CGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13895</identifier>
            <name>Ig_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>clathrin-coated endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>early endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>immunoglobulin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adaptive immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antigen processing and presentation of exogenous peptide antigen via MHC class I</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antigen processing and presentation of peptide antigen via MHC class I</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interferon-gamma-mediated signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0002098</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P12318" source="Swiss-Prot">
        <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
        <general-function/>
        <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.</specific-function>
        <gene-name>FCGR2A</gene-name>
        <locus>1q23</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>218-240</transmembrane-regions>
        <signal-regions>1-33</signal-regions>
        <theoretical-pi>6.78</theoretical-pi>
        <molecular-weight>35000.42</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3616</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FCGR2A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M31932</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>182474</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P12318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FCG2A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CD32</synonym>
          <synonym>CDw32</synonym>
          <synonym>Fc-gamma RII-a</synonym>
          <synonym>Fc-gamma-RIIa</synonym>
          <synonym>FCG2</synonym>
          <synonym>FCGR2A1</synonym>
          <synonym>FcRII-a</synonym>
          <synonym>IGFR2</synonym>
          <synonym>IgG Fc receptor II-a</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a
MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS
HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
KNIYLTLPPNDHVNSNN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)
ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
AAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13895</identifier>
            <name>Ig_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0002099</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P31994" source="Swiss-Prot">
        <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
        <general-function/>
        <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.</specific-function>
        <gene-name>FCGR2B</gene-name>
        <locus>1q23</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>218-240</transmembrane-regions>
        <signal-regions>1-42</signal-regions>
        <theoretical-pi>6.12</theoretical-pi>
        <molecular-weight>34043.355</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3618</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FCGR2B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U87560</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4099445</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P31994</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FCG2B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CD32</synonym>
          <synonym>CDw32</synonym>
          <synonym>Fc-gamma RII-b</synonym>
          <synonym>Fc-gamma-RIIb</synonym>
          <synonym>FCG2</synonym>
          <synonym>FcRII-b</synonym>
          <synonym>IGFR2</synonym>
          <synonym>IgG Fc receptor II-b</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
LEEPDDQNRI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG
CTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC
ATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC
AAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC
GACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG
TTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC
AAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC
TCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC
TACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG
ATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA
GTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG
GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
CTGGAAGAGCCTGATGACCAGAACCGTATTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13895</identifier>
            <name>Ig_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0002100</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P31995" source="Swiss-Prot">
        <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
        <general-function>Transmembrane signaling receptor activity</general-function>
        <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.</specific-function>
        <gene-name>FCGR2C</gene-name>
        <locus>1q23.3</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions>224-246</transmembrane-regions>
        <signal-regions>1-42</signal-regions>
        <theoretical-pi>6.9</theoretical-pi>
        <molecular-weight>35577.96</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:15626</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FCGR2C</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X17652</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>32074</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P31995</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FCG2C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CD32</synonym>
          <synonym>CDw32</synonym>
          <synonym>Fc-gamma RII-c</synonym>
          <synonym>Fc-gamma-RIIc</synonym>
          <synonym>FCG2</synonym>
          <synonym>FcRII-c</synonym>
          <synonym>IGFR2</synonym>
          <synonym>IgG Fc receptor II-c</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
GTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
TCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
GCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC
AGTAATAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13895</identifier>
            <name>Ig_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane signaling receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0002097</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P08637" source="Swiss-Prot">
        <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
        <general-function/>
        <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.</specific-function>
        <gene-name>FCGR3A</gene-name>
        <locus>1q23</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>209-229</transmembrane-regions>
        <signal-regions>1-16</signal-regions>
        <theoretical-pi>8.21</theoretical-pi>
        <molecular-weight>29088.895</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3619</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FCGR3A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X52645</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31324</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FCG3A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CD16A</synonym>
          <synonym>CD16a antigen</synonym>
          <synonym>Fc-gamma RIII</synonym>
          <synonym>Fc-gamma RIII-alpha</synonym>
          <synonym>Fc-gamma RIIIa</synonym>
          <synonym>FCG3</synonym>
          <synonym>FCGR3</synonym>
          <synonym>FcR-10</synonym>
          <synonym>FcRIII</synonym>
          <synonym>FcRIIIa</synonym>
          <synonym>IGFR3</synonym>
          <synonym>IgG Fc receptor III-2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
KDHKFKWRKDPQDK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)
ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT
TTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG
CTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA
AAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT
CTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG
AGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT
GGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC
CATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT
CACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT
GGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC
AAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG
ACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA
CCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA
CTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA
TTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13895</identifier>
            <name>Ig_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of immune response</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0000901</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="O75015" source="Swiss-Prot">
        <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
        <general-function/>
        <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.</specific-function>
        <gene-name>FCGR3B</gene-name>
        <locus>1q23</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-16</signal-regions>
        <theoretical-pi>6.71</theoretical-pi>
        <molecular-weight>26215.64</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3620</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FCGR3B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X16863</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31322</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O75015</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FCG3B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CD16B</synonym>
          <synonym>Fc-gamma RIII</synonym>
          <synonym>Fc-gamma RIII-beta</synonym>
          <synonym>Fc-gamma RIIIb</synonym>
          <synonym>FCG3</synonym>
          <synonym>FCGR3</synonym>
          <synonym>FcR-10</synonym>
          <synonym>FcRIII</synonym>
          <synonym>FcRIIIb</synonym>
          <synonym>IGFR3</synonym>
          <synonym>IgG Fc receptor III-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)
ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
TTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13895</identifier>
            <name>Ig_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>anchored component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitophagy in response to mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of defense response to virus by host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenophagy</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="8">
      <id>BE0003455</id>
      <name>Complement C3</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P01024" source="Swiss-Prot">
        <name>Complement C3</name>
        <general-function>Receptor binding</general-function>
        <specific-function>C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.C3-beta-c: Acts as a chemoattractant for neutrophils in chronic inflammation.Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).</specific-function>
        <gene-name>C3</gene-name>
        <locus/>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi>6.34</theoretical-pi>
        <molecular-weight>187146.73</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>C3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AY513239</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P01024</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CO3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1</synonym>
          <synonym>CPAMD1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020692|Complement C3
MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVH
DFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKV
VLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSL
SSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTE
KFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEV
VLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKT
PKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPL
SITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMD
RAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGA
SGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDK
GVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAEL
QCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEAC
KKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKE
PPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVV
RNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVI
VPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKE
DIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTP
TVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTA
YVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKD
MALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMG
RLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQR
YYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLR
SEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDA
KNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSD
RNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDG
KLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDE
YIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSY
IIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020693|Complement C3 (C3)
ATGGGACCCACCTCAGGTCCCAGCCTGCTGCTCCTGCTACTAACCCACCTCCCCCTGGCT
CTGGGGAGTCCCATGTACTCTATCATCACCCCCAACATCTTGCGGCTGGAGAGCGAGGAG
ACCATGGTGCTGGAGGCCCACGACGCGCAAGGGGATGTTCCAGTCACTGTTACTGTCCAC
GACTTCCCAGGCAAAAAACTAGTGCTGTCCAGTGAGAAGACTGTGCTGACCCCTGCCACC
AACCACATGGGCAACGTCACCTTCACGATCCCAGCCAACAGGGAGTTCAAGTCAGAAAAG
GGGCGCAACAAGTTCGTGACCGTGCAGGCCACCTTCGGGACCCAAGTGGTGGAGAAGGTG
GTGCTGGTCAGCCTGCAGAGCGGGTACCTCTTCATCCAGACAGACAAGACCATCTACACC
CCTGGCTCCACAGTTCTCTATCGGATCTTCACCGTCAACCACAAGCTGCTACCCGTGGGC
CGGACGGTCATGGTCAACATTGAGAACCCGGAAGGCATCCCGGTCAAGCAGGACTCCTTG
TCTTCTCAGAACCAGCTTGGCGTCTTGCCCTTGTCTTGGGACATTCCGGAACTCGTCAAC
ATGGGCCAGTGGAAGATCCGAGCCTACTATGAAAACTCACCACAGCAGGTCTTCTCCACT
GAGTTTGAGGTGAAGGAGTACGTGCTGCCCAGTTTCGAGGTCATAGTGGAGCCTACAGAG
AAATTCTACTACATCTATAACGAGAAGGGCCTGGAGGTCACCATCACCGCCAGGTTCCTC
TACGGGAAGAAAGTGGAGGGAACTGCCTTTGTCATCTTCGGGATCCAGGATGGCGAACAG
AGGATTTCCCTGCCTGAATCCCTCAAGCGCATTCCGATTGAGGATGGCTCGGGGGAGGTT
GTGCTGAGCCGGAAGGTACTGCTGGACGGGGTGCAGAACCCCCGAGCAGAAGACCTGGTG
GGGAAGTCTTTGTACGTGTCTGCCACCGTCATCTTGCACTCAGGCAGTGACATGGTGCAG
GCAGAGCGCAGCGGGATCCCCATCGTGACCTCTCCCTACCAGATCCACTTCACCAAGACA
CCCAAGTACTTCAAACCAGGAATGCCCTTTGACCTCATGGTGTTCGTGACGAACCCTGAT
GGCTCTCCAGCCTACCGAGTCCCCGTGGCAGTCCAGGGCGAGGACACTGTGCAGTCTCTA
ACCCAGGGAGATGGCGTGGCCAAACTCAGCATCAACACACACCCCAGCCAGAAGCCCTTG
AGCATCACGGTGCGCACGAAGAAGCAGGAGCTCTCGGAGGCAGAGCAGGCTACCAGGACC
ATGCAGGCTCTGCCCTACAGCACCGTGGGCAACTCCAACAATTACCTGCATCTCTCAGTG
CTACGTACAGAGCTCAGACCCGGGGAGACCCTCAACGTCAACTTCCTCCTGCGAATGGAC
CGCGCCCACGAGGCCAAGATCCGCTACTACACCTACCTGATCATGAACAAGGGCAGGCTG
TTGAAGGCGGGACGCCAGGTGCGAGAGCCCGGCCAGGACCTGGTGGTGCTGCCCCTGTCC
ATCACCACCGACTTCATCCCTTCCTTCCGCCTGGTGGCGTACTACACGCTGATCGGTGCC
AGCGGCCAGAGGGAGGTGGTGGCCGACTCCGTGTGGGTGGACGTCAAGGACTCCTGCGTG
GGCTCGCTGGTGGTAAAAAGCGGCCAGTCAGAAGACCGGCAGCCTGTACCTGGGCAGCAG
ATGACCCTGAAGATAGAGGGTGACCACGGGGCCCGGGTGGTACTGGTGGCCGTGGACAAG
GGCGTGTTCGTGCTGAATAAGAAGAACAAACTGACGCAGAGTAAGATCTGGGACGTGGTG
GAGAAGGCAGACATCGGCTGCACCCCGGGCAGTGGGAAGGATTACGCCGGTGTCTTCTCC
GACGCAGGGCTGACCTTCACGAGCAGCAGTGGCCAGCAGACCGCCCAGAGGGCAGAACTT
CAGTGCCCGCAGCCAGCCGCCCGCCGACGCCGTTCCGTGCAGCTCACGGAGAAGCGAATG
GACAAAGTCGGCAAGTACCCCAAGGAGCTGCGCAAGTGCTGCGAGGACGGCATGCGGGAG
AACCCCATGAGGTTCTCGTGCCAGCGCCGGACCCGTTTCATCTCCCTGGGCGAGGCGTGC
AAGAAGGTCTTCCTGGACTGCTGCAACTACATCACAGAGCTGCGGCGGCAGCACGCGCGG
GCCAGCCACCTGGGCCTGGCCAGGAGTAACCTGGATGAGGACATCATTGCAGAAGAGAAC
ATCGTTTCCCGAAGTGAGTTCCCAGAGAGCTGGCTGTGGAACGTTGAGGACTTGAAAGAG
CCACCGAAAAATGGAATCTCTACGAAGCTCATGAATATATTTTTGAAAGACTCCATCACC
ACGTGGGAGATTCTGGCTGTGAGCATGTCGGACAAGAAAGGGATCTGTGTGGCAGACCCC
TTCGAGGTCACAGTAATGCAGGACTTCTTCATCGACCTGCGGCTACCCTACTCTGTTGTT
CGAAACGAGCAGGTGGAAATCCGAGCCGTTCTCTACAATTACCGGCAGAACCAAGAGCTC
AAGGTGAGGGTGGAACTACTCCACAATCCAGCCTTCTGCAGCCTGGCCACCACCAAGAGG
CGTCACCAGCAGACCGTAACCATCCCCCCCAAGTCCTCGTTGTCCGTTCCATATGTCATC
GTGCCGCTAAAGACCGGCCTGCAGGAAGTGGAAGTCAAGGCTGCTGTCTACCATCATTTC
ATCAGTGACGGTGTCAGGAAGTCCCTGAAGGTCGTGCCGGAAGGAATCAGAATGAACAAA
ACTGTGGCTGTTCGCACCCTGGATCCAGAACGCCTGGGCCGTGAAGGAGTGCAGAAAGAG
GACATCCCACCTGCAGACCTCAGTGACCAAGTCCCGGACACCGAGTCTGAGACCAGAATT
CTCCTGCAAGGGACCCCAGTGGCCCAGATGACAGAGGATGCCGTCGACGCGGAACGGCTG
AAGCACCTCATTGTGACCCCCTCGGGCTGCGGGGAACAGAACATGATCGGCATGACGCCC
ACGGTCATCGCTGTGCATTACCTGGATGAAACGGAGCAGTGGGAGAAGTTCGGCCTAGAG
AAGCGGCAGGGGGCCTTGGAGCTCATCAAGAAGGGGTACACCCAGCAGCTGGCCTTCAGA
CAACCCAGCTCTGCCTTTGCGGCCTTCGTGAAACGGGCACCCAGCACCTGGCTGACCGCC
TACGTGGTCAAGGTCTTCTCTCTGGCTGTCAACCTCATCGCCATCGACTCCCAAGTCCTC
TGCGGGGCTGTTAAATGGCTGATCCTGGAGAAGCAGAAGCCCGACGGGGTCTTCCAGGAG
GATGCGCCCGTGATACACCAAGAAATGATTGGTGGATTACGGAACAACAACGAGAAAGAC
ATGGCCCTCACGGCCTTTGTTCTCATCTCGCTGCAGGAGGCTAAAGATATTTGCGAGGAG
CAGGTCAACAGCCTGCCAGGCAGCATCACTAAAGCAGGAGACTTCCTTGAAGCCAACTAC
ATGAACCTACAGAGATCCTACACTGTGGCCATTGCTGGCTATGCTCTGGCCCAGATGGGC
AGGCTGAAGGGGCCTCTTCTTAACAAATTTCTGACCACAGCCAAAGATAAGAACCGCTGG
GAGGACCCTGGTAAGCAGCTCTACAACGTGGAGGCCACATCCTATGCCCTCTTGGCCCTA
CTGCAGCTAAAAGACTTTGACTTTGTGCCTCCCGTCGTGCGTTGGCTCAATGAACAGAGA
TACTACGGTGGTGGCTATGGCTCTACCCAGGCCACCTTCATGGTGTTCCAAGCCTTGGCT
CAATACCAAAAGGACGCCCCTGACCACCAGGAACTGAACCTTGATGTGTCCCTCCAACTG
CCCAGCCGCAGCTCCAAGATCACCCACCGTATCCACTGGGAATCTGCCAGCCTCCTGCGA
TCAGAAGAGACCAAGGAAAATGAGGGTTTCACAGTCACAGCTGAAGGAAAAGGCCAAGGC
ACCTTGTCGGTGGTGACAATGTACCATGCTAAGGCCAAAGATCAACTCACCTGTAATAAA
TTCGACCTCAAGGTCACCATAAAACCAGCACCGGAAACAGAAAAGAGGCCTCAGGATGCC
AAGAACACTATGATCCTTGAGATCTGTACCAGGTACCGGGGAGACCAGGATGCCACTATG
TCTATATTGGACATATCCATGATGACTGGCTTTGCTCCAGACACAGATGACCTGAAGCAG
CTGGCCAATGGTGTTGACAGATACATCTCCAAGTATGAGCTGGACAAAGCCTTCTCCGAT
AGGAACACCCTCATCATCTACCTGGACAAGGTCTCACACTCTGAGGATGACTGTCTAGCT
TTCAAAGTTCACCAATACTTTAATGTAGAGCTTATCCAGCCTGGAGCAGTCAAGGTCTAC
GCCTATTACAACCTGGAGGAAAGCTGTACCCGGTTCTACCATCCGGAAAAGGAGGATGGA
AAGCTGAACAAGCTCTGCCGTGATGAACTGTGCCGCTGTGCTGAGGAGAATTGCTTCATA
CAAAAGTCGGATGACAAGGTCACCCTGGAAGAACGGCTGGACAAGGCCTGTGAGCCAGGA
GTGGACTATGTGTACAAGACCCGACTGGTCAAGGTTCAGCTGTCCAATGACTTTGACGAG
TACATCATGGCCATTGAGCAGACCATCAAGTCAGGCTCGGATGAGGTGCAGGTTGGACAG
CAGCGCACGTTCATCAGCCCCATCAAGTGCAGAGAAGCCCTGAAGCTGGAGGAGAAGAAA
CACTACCTCATGTGGGGTCTCTCCTCCGATTTCTGGGGAGAGAAGCCCAACCTCAGCTAC
ATCATCGGGAAGGACACTTGGGTGGAGCACTGGCCCGAGGAGGACGAATGCCAAGACGAA
GAGAACCAGAAACAATGCCAGGACCTCGGCGCCTTCACCGAGAGCATGGTTGTCTTTGGG
TGCCCCAACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00207</identifier>
            <name>A2M</name>
          </pfam>
          <pfam>
            <identifier>PF07678</identifier>
            <name>A2M_comp</name>
          </pfam>
          <pfam>
            <identifier>PF01835</identifier>
            <name>A2M_N</name>
          </pfam>
          <pfam>
            <identifier>PF07703</identifier>
            <name>A2M_N_2</name>
          </pfam>
          <pfam>
            <identifier>PF07677</identifier>
            <name>A2M_recep</name>
          </pfam>
          <pfam>
            <identifier>PF01821</identifier>
            <name>ANATO</name>
          </pfam>
          <pfam>
            <identifier>PF01759</identifier>
            <name>NTR</name>
          </pfam>
          <pfam>
            <identifier>PF10569</identifier>
            <name>Thiol-ester_cl</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>C5L2 anaphylatoxin chemotactic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cofactor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>endopeptidase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation, alternative pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation, classical pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of activation of membrane attack complex</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic cell clearance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of developmental growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of G-protein coupled receptor protein signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glucose transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of lipid storage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of type IIa hypersensitivity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of complement activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of triglyceride biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to magnesium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to progesterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tolerance induction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="11">
      <id>BE0004685</id>
      <name>Complement C4-A</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0C0L4" source="Swiss-Prot">
        <name>Complement C4-A</name>
        <general-function>Endopeptidase inhibitor activity</general-function>
        <specific-function>Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.</specific-function>
        <gene-name>C4A</gene-name>
        <locus/>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi/>
        <molecular-weight>192783.805</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1323</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0C0L4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CO4A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Acidic complement C4</synonym>
          <synonym>C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2</synonym>
          <synonym>CO4</synonym>
          <synonym>CPAMD2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009602|Complement C4-A
MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN
PSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS
LSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN
SHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN
FEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE
SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW
YFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD
IQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS
RPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS
FYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA
LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW
TLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA
ARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE
NWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP
MSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS
VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI
PGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP
TLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTA
FVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVA
LTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKANSFLGEKASAGLLGAHAAAITAYAL
TLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL
WIETTAYALLHLLLHEGKAEMADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH
TTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV
LRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP
LQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD
LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY
NPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY
PRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG
KEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ
GCQV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013260|Complement C4-A (C4A)
ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAG
CCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGG
GTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAAC
CCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGA
GACTTCGCACTCCTCAGTCTCCAGGTGCCCTTGAAAGATGCGAAGAGCTGTGGCCTCCAT
CAACTCCTCAGAGGCCCTGAGGTCCAGCTGGTGGCCCATTCGCCATGGCTAAAGGACTCT
CTGTCCAGAACGACAAACATCCAGGGTATCAACCTGCTCTTCTCCTCTCGCCGGGGGCAC
CTCTTTTTGCAGACGGACCAGCCCATTTACAACCCTGGCCAGCGGGTTCGGTACCGGGTC
TTTGCTCTGGATCAGAAGATGCGCCCGAGCACTGACACCATCACAGTCATGGTGGAGAAC
TCTCACGGCCTCCGCGTGCGGAAGAAGGAGGTGTACATGCCCTCGTCCATCTTCCAGGAT
GACTTTGTGATCCCAGACATCTCAGAGCCAGGGACCTGGAAGATCTCAGCCCGATTCTCA
GATGGCCTGGAATCCAACAGCAGCACCCAGTTTGAGGTGAAGAAATATGTCCTTCCCAAC
TTTGAGGTGAAGATCACCCCTGGAAAGCCCTACATCCTGACGGTGCCAGGCCATCTTGAT
GAAATGCAGTTAGACATCCAGGCCAGGTACATCTATGGGAAGCCAGTGCAGGGGGTGGCA
TATGTGCGCTTTGGGCTCCTAGATGAGGATGGTAAGAAGACTTTCTTTCGGGGGCTGGAG
AGTCAGACCAAGCTGGTGAATGGACAGAGCCACATTTCCCTCTCAAAGGCAGAGTTCCAG
GACGCCCTGGAGAAGCTGAATATGGGCATTACTGACCTCCAGGGGCTGCGCCTCTACGTT
GCTGCAGCCATCATTGAGTCTCCAGGTGGGGAGATGGAGGAGGCAGAGCTCACATCCTGG
TATTTTGTGTCATCTCCCTTCTCCTTGGATCTTAGCAAGACCAAGCGACACCTTGTGCCT
GGGGCCCCCTTCCTGCTGCAGGCCTTGGTCCGTGAGATGTCAGGCTCCCCAGCTTCTGGC
ATTCCTGTCAAAGTTTCTGCCACGGTGTCTTCTCCTGGGTCTGTTCCTGAAGTCCAGGAC
ATTCAGCAAAACACAGACGGGAGCGGCCAAGTCAGCATTCCAATAATTATCCCTCAGACC
ATCTCAGAGCTGCAGCTCTCAGTATCTGCAGGCTCCCCACATCCAGCGATAGCCAGGCTC
ACTGTGGCAGCCCCACCTTCAGGAGGCCCCGGGTTTCTGTCTATTGAGCGGCCGGATTCT
CGACCTCCTCGTGTTGGGGACACTCTGAACCTGAACTTGCGAGCCGTGGGCAGTGGGGCC
ACCTTTTCTCATTACTACTACATGATCCTATCCCGAGGGCAGATCGTGTTCATGAATCGA
GAGCCCAAGAGGACCCTGACCTCGGTCTCGGTGTTTGTGGACCATCACCTGGCACCCTCC
TTCTACTTTGTGGCCTTCTACTACCATGGAGACCACCCAGTGGCCAACTCCCTGCGAGTG
GATGTCCAGGCTGGGGCCTGCGAGGGCAAGCTGGAGCTCAGCGTGGACGGTGCCAAGCAG
TACCGGAACGGGGAGTCCGTGAAGCTCCACTTAGAAACCGACTCCCTAGCCCTGGTGGCG
CTGGGAGCCTTGGACACAGCTCTGTATGCTGCAGGCAGCAAGTCCCACAAGCCCCTCAAC
ATGGGCAAGGTCTTTGAAGCTATGAACAGCTATGACCTCGGCTGTGGTCCTGGGGGTGGG
GACAGTGCCCTTCAGGTGTTCCAGGCAGCGGGCCTGGCCTTTTCTGATGGAGACCAGTGG
ACCTTATCCAGAAAGAGACTAAGCTGTCCCAAGGAGAAGACAACCCGGAAAAAGAGAAAC
GTGAACTTCCAAAAGGCGATTAATGAGAAATTGGGTCAGTATGCTTCCCCGACAGCCAAG
CGCTGCTGCCAGGATGGGGTGACACGTCTGCCCATGATGCGTTCCTGCGAGCAGCGGGCA
GCCCGCGTGCAGCAGCCGGACTGCCGGGAGCCCTTCCTGTCCTGCTGCCAATTTGCTGAG
AGTCTGCGCAAGAAGAGCAGGGACAAGGGCCAGGCGGGCCTCCAACGAGCCCTGGAGATC
CTGCAGGAGGAGGACCTGATTGATGAGGATGACATTCCCGTGCGCAGCTTCTTCCCAGAG
AACTGGCTCTGGAGAGTGGAAACAGTGGACCGCTTTCAAATATTGACACTGTGGCTCCCC
GACTCTCTGACCACGTGGGAGATCCATGGCCTGAGCCTGTCCAAAACCAAAGGCCTATGT
GTGGCCACCCCAGTCCAGCTCCGGGTGTTCCGCGAGTTCCACCTGCACCTCCGCCTGCCC
ATGTCTGTCCGCCGCTTTGAGCAGCTGGAGCTGCGGCCTGTCCTCTATAACTACCTGGAT
AAAAACCTGACTGTGAGCGTCCACGTGTCCCCAGTGGAGGGGCTGTGCCTGGCTGGGGGC
GGAGGGCTGGCCCAGCAGGTGCTGGTGCCTGCGGGCTCTGCCCGGCCTGTTGCCTTCTCT
GTGGTGCCCACGGCAGCCGCCGCTGTGTCTCTGAAGGTGGTGGCTCGAGGGTCCTTCGAA
TTCCCTGTGGGAGATGCGGTGTCCAAGGTTCTGCAGATTGAGAAGGAAGGGGCCATCCAT
AGAGAGGAGCTGGTCTATGAACTCAACCCCTTGGACCACCGAGGCCGGACCTTGGAAATA
CCTGGCAACTCTGATCCCAATATGATCCCTGATGGGGACTTTAACAGCTACGTCAGGGTT
ACAGCCTCAGATCCATTGGACACTTTAGGCTCTGAGGGGGCCTTGTCACCAGGAGGCGTG
GCCTCCCTCTTGAGGCTTCCTCGAGGCTGTGGGGAGCAAACCATGATCTACTTGGCTCCG
ACACTGGCTGCTTCCCGCTACCTGGACAAGACAGAGCAGTGGAGCACACTGCCTCCCGAG
ACCAAGGACCACGCCGTGGATCTGATCCAGAAAGGCTACATGCGGATCCAGCAGTTTCGG
AAGGCGGATGGTTCCTATGCGGCTTGGTTGTCACGGGACAGCAGCACCTGGCTCACAGCC
TTTGTGTTGAAGGTCCTGAGTTTGGCCCAGGAGCAGGTAGGAGGCTCGCCTGAGAAACTG
CAGGAGACATCTAACTGGCTTCTGTCCCAGCAGCAGGCTGACGGCTCGTTCCAGGACCCC
TGTCCAGTGTTAGACAGGAGCATGCAGGGGGGTTTGGTGGGCAATGATGAGACTGTGGCA
CTCACAGCCTTTGTGACCATCGCCCTTCATCATGGGCTGGCCGTCTTCCAGGATGAGGGT
GCAGAGCCATTGAAGCAGAGAGTGGAAGCCTCCATCTCAAAGGCAAACTCATTTTTGGGG
GAGAAAGCAAGTGCTGGGCTCCTGGGTGCCCACGCAGCTGCCATCACGGCCTATGCCCTG
ACACTGACCAAGGCGCCTGTGGACCTGCTCGGTGTTGCCCACAACAACCTCATGGCAATG
GCCCAGGAGACTGGAGATAACCTGTACTGGGGCTCAGTCACTGGTTCTCAGAGCAATGCC
GTGTCGCCCACCCCGGCTCCTCGCAACCCATCCGACCCCATGCCCCAGGCCCCAGCCCTG
TGGATTGAAACCACAGCCTACGCCCTGCTGCACCTCCTGCTTCACGAGGGCAAAGCAGAG
ATGGCAGACCAGGCTTCGGCCTGGCTCACCCGTCAGGGCAGCTTCCAAGGGGGATTCCGC
AGTACCCAAGACACGGTGATTGCCCTGGATGCCCTGTCTGCCTACTGGATTGCCTCCCAC
ACCACTGAGGAGAGGGGTCTCAATGTGACTCTCAGCTCCACAGGCCGGAATGGGTTCAAG
TCCCACGCGCTGCAGCTGAACAACCGCCAGATTCGCGGCCTGGAGGAGGAGCTGCAGTTT
TCCTTGGGCAGCAAGATCAATGTGAAGGTGGGAGGAAACAGCAAAGGAACCCTGAAGGTC
CTTCGTACCTACAATGTCCTGGACATGAAGAACACGACCTGCCAGGACCTACAGATAGAA
GTGACAGTCAAAGGCCACGTCGAGTACACGATGGAAGCAAACGAGGACTATGAGGACTAT
GAGTACGATGAGCTTCCAGCCAAGGATGACCCAGATGCCCCTCTGCAGCCCGTGACACCC
CTGCAGCTGTTTGAGGGTCGGAGGAACCGCCGCAGGAGGGAGGCGCCCAAGCTGACCTCC
CTCTCTGACCGTTACGTGAGTCACTTTGAGACCGAGGGGCCCCACGTCCTGCTGTATTTT
GACTCGGTCCCCACCTCCCGGGAGTGCGTGGGCTTTGAGGCTGTGCAGGAAGTGCCGGTG
GGGCTGGTGCAGCCGGCCAGCGCAACCCTGTACGACTACTACAACCCCGAGCGCAGATGT
TCTGTGTTTTACGGGGCACCAAGTAAGAGCAGACTCTTGGCCACCTTGTGTTCTGCTGAA
GTCTGCCAGTGTGCTGAGGGGAAGTGCCCTCGCCAGCGTCGCGCCCTGGAGCGGGGTCTG
CAGGACGAGGATGGCTACAGGATGAAGTTTGCCTGCTACTACCCCCGTGTGGAGTACGGC
TTCCAGGTTAAGGTTCTCCGAGAAGACAGCAGAGCTGCTTTCCGCCTCTTTGAGACCAAG
ATCACCCAAGTCCTGCACTTCACCAAGGATGTCAAGGCCGCTGCTAATCAGATGCGCAAC
TTCCTGGTTCGAGCCTCCTGCCGCCTTCGCTTGGAACCTGGGAAAGAATATTTGATCATG
GGTCTGGATGGGGCCACCTATGACCTCGAGGGACACCCCCAGTACCTGCTGGACTCGAAT
AGCTGGATCGAGGAGATGCCCTCTGAACGCCTGTGCCGGAGCACCCGCCAGCGGGCAGCC
TGTGCCCAGCTCAACGACTTCCTCCAGGAGTATGGCACTCAGGGGTGCCAGGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00207</identifier>
            <name>A2M</name>
          </pfam>
          <pfam>
            <identifier>PF07678</identifier>
            <name>A2M_comp</name>
          </pfam>
          <pfam>
            <identifier>PF01835</identifier>
            <name>A2M_N</name>
          </pfam>
          <pfam>
            <identifier>PF07703</identifier>
            <name>A2M_N_2</name>
          </pfam>
          <pfam>
            <identifier>PF07677</identifier>
            <name>A2M_recep</name>
          </pfam>
          <pfam>
            <identifier>PF01821</identifier>
            <name>ANATO</name>
          </pfam>
          <pfam>
            <identifier>PF01759</identifier>
            <name>NTR</name>
          </pfam>
          <pfam>
            <identifier>PF10569</identifier>
            <name>Thiol-ester_cl</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>complement component C1q binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>endopeptidase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation, classical pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic cell clearance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of complement activation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="12">
      <id>BE0004686</id>
      <name>Complement C4-B</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0C0L5" source="Swiss-Prot">
        <name>Complement C4-B</name>
        <general-function>Non-enzymatic component of the C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.</general-function>
        <specific-function>Carbohydrate binding</specific-function>
        <gene-name>C4B</gene-name>
        <locus/>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi/>
        <molecular-weight>192749.785</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1324</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0C0L5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CO4B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Basic complement C4</synonym>
          <synonym>C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3</synonym>
          <synonym>CO4</synonym>
          <synonym>CPAMD3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009603|Complement C4-B
MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN
PSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS
LSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN
SHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN
FEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE
SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW
YFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD
IQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS
RPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS
FYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA
LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW
TLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA
ARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE
NWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP
MSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS
VVPTAATAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI
PGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP
TLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRGSSTWLTA
FVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDLSPVIHRSMQGGLVGNDETVA
LTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL
TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL
WIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH
TTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV
LRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP
LQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD
LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY
NPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY
PRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG
KEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ
GCQV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017510|Complement C4-B (C4B)
ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAG
CCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGG
GTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAAC
CCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGA
GACTTCGCACTCCTCAGTCTCCAGGTGCCCTTGAAAGATGCGAAGAGCTGTGGCCTCCAT
CAACTCCTCAGAGGCCCTGAGGTCCAGCTGGTGGCCCATTCGCCATGGCTAAAGGACTCT
CTGTCCAGAACGACAAACATCCAGGGTATCAACCTGCTCTTCTCCTCTCGCCGGGGGCAC
CTCTTTTTGCAGACGGACCAGCCCATTTACAACCCTGGCCAGCGGGTTCGGTACCGGGTC
TTTGCTCTGGATCAGAAGATGCGCCCGAGCACTGACACCATCACAGTCATGGTGGAGAAC
TCTCACGGCCTCCGCGTGCGGAAGAAGGAGGTGTACATGCCCTCGTCCATCTTCCAGGAT
GACTTTGTGATCCCAGACATCTCAGAGCCAGGGACCTGGAAGATCTCAGCCCGATTCTCA
GATGGCCTGGAATCCAACAGCAGCACCCAGTTTGAGGTGAAGAAATATGTCCTTCCCAAC
TTTGAGGTGAAGATCACCCCTGGAAAGCCCTACATCCTGACGGTGCCAGGCCATCTTGAT
GAAATGCAGTTAGACATCCAGGCCAGGTACATCTATGGGAAGCCAGTGCAGGGGGTGGCA
TATGTGCGCTTTGGGCTCCTAGATGAGGATGGTAAGAAGACTTTCTTTCGGGGGCTGGAG
AGTCAGACCAAGCTGGTGAATGGACAGAGCCACATTTCCCTCTCAAAGGCAGAGTTCCAG
GACGCCCTGGAGAAGCTGAATATGGGCATTACTGACCTCCAGGGGCTGCGCCTCTACGTT
GCTGCAGCCATCATTGAGTATCCAGGTGGGGAGATGGAGGAGGCAGAGCTCACATCCTGG
TATTTTGTGTCATCTCCCTTCTCCTTGGATCTTAGCAAGACCAAGCGACACCTTGTGCCT
GGGGCCCCCTTCCTGCTGCAGGCCTTGGTCCGTGAGATGTCAGGCTCCCCAGCTTCTGGC
ATTCCTGTCAAAGTTTCTGCCACGGTGTCTTCTCCTGGGTCTGTTCCTGAAGTCCAGGAC
ATTCAGCAAAACACAGACGGGAGCGGCCAAGTCAGCATTCCAATAATTATCCCTCAGACC
ATCTCAGAGCTGCAGCTCTCAGTATCTGCAGGCTCCCCACATCCAGCGATAGCCAGGCTC
ACTGTGGCAGCCCCACCTTCAGGAGGCCCCGGGTTTCTGTCTATTGAGCGGCCGGATTCT
CGACCTCCTCGTGTTGGGGACACTCTGAACCTGAACTTGCGAGCCGTGGGCAGTGGGGCC
ACCTTTTCTCATTACTACTACATGATCCTATCCCGAGGGCAGATCGTGTTCATGAATCGA
GAGCCCAAGAGGACCCTGACCTCGGTCTCGGTGTTTGTGGACCATCACCTGGCACCCTCC
TTCTACTTTGTGGCCTTCTACTACCATGGAGACCACCCAGTGGCCAACTCCCTGCGAGTG
GATGTCCAGGCTGGGGCCTGCGAGGGCAAGCTGGAGCTCAGCGTGGACGGTGCCAAGCAG
TACCGGAACGGGGAGTCCGTGAAGCTCCACTTAGAAACCGACTCCCTAGCCCTGGTGGCG
CTGGGAGCCTTGGACACAGCTCTGTATGCTGCAGGCAGCAAGTCCCACAAGCCCCTCAAC
ATGGGCAAGGTCTTTGAAGCTATGAACAGCTATGACCTCGGCTGTGGTCCTGGGGGTGGG
GACAGTGCCCTTCAGGTGTTCCAGGCAGCGGGCCTGGCCTTTTCTGATGGAGACCAGTGG
ACCTTATCCAGAAAGAGACTAAGCTGTCCCAAGGAGAAGACAACCCGGAAAAAGAGAAAC
GTGAACTTCCAAAAGGCGATTAATGAGAAATTGGGTCAGTATGCTTCCCCGACAGCCAAG
CGCTGCTGCCAGGATGGGGTGACACGTCTGCCCATGATGCGTTCCTGCGAGCAGCGGGCA
GCCCGCGTGCAGCAGCCGGACTGCCGGGAGCCCTTCCTGTCCTGCTGCCAATTTGCTGAG
AGTCTGCGCAAGAAGAGCAGGGACAAGGGCCAGGCGGGCCTCCAACGAGCCCTGGAGATC
CTGCAGGAGGAGGACCTGATTGATGAGGATGACATTCCCGTGCGCAGCTTCTTCCCAGAG
AACTGGCTCTGGAGAGTGGAAACAGTGGACCGCTTTCAAATATTGACACTGTGGCTCCCC
GACTCTCTGACCACGTGGGAGATCCATGGCCTGAGCCTGTCCAAAACCAAAGGCCTATGT
GTGGCCACCCCAGTCCAGCTCCGGGTGTTCCGCGAGTTCCACCTGCACCTCCGCCTGCCC
ATGTCTGTCCGCCGCTTTGAGCAGCTGGAGCTGCGGCCTGTCCTCTATAACTACCTGGAT
AAAAACCTGACTGTGAGCGTCCACGTGTCCCCAGTGGAGGGGCTGTGCCTGGCTGGGGGC
GGAGGGCTGGCCCAGCAGGTGCTGGTGCCTGCGGGCTCTGCCCGGCCTGTTGCCTTCTCT
GTGGTGCCCACGGCAGCCGCCGCTGTGTCTCTGAAGGTGGTGGCTCGAGGGTCCTTCGAA
TTCCCTGTGGGAGATGCGGTGTCCAAGGTTCTGCAGATTGAGAAGGAAGGGGCCATCCAT
AGAGAGGAGCTGGTCTATGAACTCAACCCCTTGGACCACCGAGGCCGGACCTTGGAAATA
CCTGGCAACTCTGATCCCAATATGATCCCTGATGGGGACTTTAACAGCTACGTCAGGGTT
ACAGCCTCAGATCCATTGGACACTTTAGGCTCTGAGGGGGCCTTGTCACCAGGAGGCGTG
GCCTCCCTCTTGAGGCTTCCTCGAGGCTGTGGGGAGCAAACCATGATCTACTTGGCTCCG
ACACTGGCTGCTTCCCGCTACCTGGACAAGACAGAGCAGTGGAGCACACTGCCTCCCGAG
ACCAAGGACCACGCCGTGGATCTGATCCAGAAAGGCTACATGCGGATCCAGCAGTTTCGG
AAGGCGGATGGTTCCTATGCGGCTTGGTTGTCACGGGGCAGCAGCACCTGGCTCACAGCC
TTTGTGTTGAAGGTCCTGAGTTTGGCCCAGGAGCAGGTAGGAGGCTCGCCTGAGAAACTG
CAGGAGACATCTAACTGGCTTCTGTCCCAGCAGCAGGCTGACGGCTCGTTCCAGGACCTC
TCTCCAGTGATACATAGGAGCATGCAGGGGGGTTTGGTGGGCAATGATGAGACTGTGGCA
CTCACAGCCTTTGTGACCATCGCCCTTCATCATGGGCTGGCCGTCTTCCAGGATGAGGGT
GCAGAGCCATTGAAGCAGAGAGTGGAAGCCTCCATCTCAAAGGCAAGCTCATTTTTGGGG
GAGAAAGCAAGTGCTGGGCTCCTGGGTGCCCACGCAGCTGCCATCACGGCCTATGCCCTG
ACACTGACCAAGGCCCCTGCGGACCTGCGGGGTGTTGCCCACAACAACCTCATGGCAATG
GCCCAGGAGACTGGAGATAACCTGTACTGGGGCTCAGTCACTGGTTCTCAGAGCAATGCC
GTGTCGCCCACCCCAGCTCCTCGCAACCCATCCGACCCCATGCCCCAGGCCCCAGCCCTG
TGGATTGAAACCACAGCCTACGCCCTGCTGCACCTCCTGCTTCACGAGGGCAAAGCAGAG
ATGGCAGACCAGGCTGCGGCCTGGCTCACCCGTCAGGGCAGCTTCCAAGGGGGATTCCGC
AGTACCCAAGACACGGTGATTGCCCTGGATGCCCTGTCTGCCTACTGGATTGCCTCCCAC
ACCACTGAGGAGAGGGGTCTCAATGTGACTCTCAGCTCCACAGGCCGGAATGGGTTCAAG
TCCCACGCGCTGCAGCTGAACAACCGCCAGATTCGCGGCCTGGAGGAGGAGCTGCAGTTT
TCCTTGGGCAGCAAGATCAATGTGAAGGTGGGAGGAAACAGCAAAGGAACCCTGAAGGTC
CTTCGTACCTACAATGTCCTGGACATGAAGAACACGACCTGCCAGGACCTACAGATAGAA
GTGACAGTCAAAGGCCACGTCGAGTACACGATGGAAGCAAACGAGGACTATGAGGACTAT
GAGTACGATGAGCTTCCAGCCAAGGATGACCCAGATGCCCCTCTGCAGCCCGTGACACCC
CTGCAGCTGTTTGAGGGTCGGAGGAACCGCCGCAGGAGGGAGGCGCCCAAGGTGGTGGAG
GAGCAGGAGTCCAGGGTGCACTACACCGTGTGCATCTGGCGGAACGGCAAGGTGGGGCTG
TCTGGCATGGCCATCGCGGACGTCACCCTCCTGAGTGGATTCCACGCCCTGCGTGCTGAC
CTGGAGAAGCTGACCTCCCTCTCTGACCGTTACGTGAGTCACTTTGAGACCGAGGGGCCC
CACGTCCTGCTGTATTTTGACTCGGTCCCCACCTCCCGGGAGTGCGTGGGCTTTGAGGCT
GTGCAGGAAGTGCCGGTGGGGCTGGTGCAGCCGGCCAGCGCAACCCTGTACGACTACTAC
AACCCCGAGCGCAGATGTTCTGTGTTTTACGGGGCACCAAGTAAGAGCAGACTCTTGGCC
ACCTTGTGTTCTGCTGAAGTCTGCCAGTGTGCTGAGGGGAAGTGCCCTCGCCAGCGTCGC
GCCCTGGAGCGGGGTCTGCAGGACGAGGATGGCTACAGGATGAAGTTTGCCTGCTACTAC
CCCCGTGTGGAGTACGGCTTCCAGGTTAAGGTTCTCCGAGAAGACAGCAGAGCTGCTTTC
CGCCTCTTTGAGACCAAGATCACCCAAGTCCTGCACTTCACCAAGGATGTCAAGGCCGCT
GCTAATCAGATGCGCAACTTCCTGGTTCGAGCCTCCTGCCGCCTTCGCTTGGAACCTGGG
AAAGAATATTTGATCATGGGTCTAGATGGGGCCACCTATGACCTCGAGGGACACCCCCAG
TACCTGCTGGACTCGAATAGCTGGATCGAGGAGATGCCCTCTGAACGCCTGTGCCGGAGC
ACCCGCCAGCGGGCAGCCTGTGCCCAGCTCAACGACTTCCTCCAGGAGTATGGCACTCAG
GGGTGCCAGGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00207</identifier>
            <name>A2M</name>
          </pfam>
          <pfam>
            <identifier>PF07678</identifier>
            <name>A2M_comp</name>
          </pfam>
          <pfam>
            <identifier>PF01835</identifier>
            <name>A2M_N</name>
          </pfam>
          <pfam>
            <identifier>PF07703</identifier>
            <name>A2M_N_2</name>
          </pfam>
          <pfam>
            <identifier>PF07677</identifier>
            <name>A2M_recep</name>
          </pfam>
          <pfam>
            <identifier>PF01821</identifier>
            <name>ANATO</name>
          </pfam>
          <pfam>
            <identifier>PF01759</identifier>
            <name>NTR</name>
          </pfam>
          <pfam>
            <identifier>PF10569</identifier>
            <name>Thiol-ester_cl</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>other organism cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carbohydrate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>complement binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>endopeptidase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation, classical pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of molecule of bacterial origin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>opsonization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic cell clearance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of complement activation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="12">
      <id>BE0000855</id>
      <name>Complement C5</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A13124</ref-id>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <ref-id>A13125</ref-id>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
          <article>
            <ref-id>A37</ref-id>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P01031" source="Swiss-Prot">
        <name>Complement C5</name>
        <general-function>Receptor binding</general-function>
        <specific-function>Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.</specific-function>
        <gene-name>C5</gene-name>
        <locus>9q33-q34</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.49</theoretical-pi>
        <molecular-weight>188303.705</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1331</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>C5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M57729</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>179983</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P01031</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CO5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4</synonym>
          <synonym>CPAMD4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019020|Complement C5
MGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYP
DKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPIT
YDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHI
GIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGY
KNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVT
FDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATP
LFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASF
VLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGE
HLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRL
LVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWV
ALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANAD
DSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISL
GPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLV
PRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQ
LKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTV
LPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFP
YRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFY
VFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTA
FALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEAREN
SLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDK
THPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLN
LKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHK
GALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLK
IDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLK
ALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHR
PDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYA
YKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIM
GKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019021|Complement C5 (C5)
ATGGGCCTTTTGGGAATACTTTGTTTTTTAATCTTCCTGGGGAAAACCTGGGGACAGGAG
CAAACATATGTCATTTCAGCACCAAAAATATTCCGTGTTGGAGCATCTGAAAATATTGTG
ATTCAAGTTTATGGATACACTGAAGCATTTGATGCAACAATCTCTATTAAAAGTTATCCT
GATAAAAAATTTAGTTACTCCTCAGGCCATGTTCATTTATCCTCAGAGAATAAATTCCAA
AACTCTGCAATCTTAACAATACAACCAAAACAATTGCCTGGAGGACAAAACCCAGTTTCT
TATGTGTATTTGGAAGTTGTATCAAAGCATTTTTCAAAATCAAAAAGAATGCCAATAACC
TATGACAATGGATTTCTCTTCATTCATACAGACAAACCTGTTTATACTCCAGACCAGTCA
GTAAAAGTTAGAGTTTATTCGTTGAATGACGACTTGAAGCCAGCCAAAAGAGAAACTGTC
TTAACTTTCATAGATCCTGAAGGATCAGAAGTTGACATGGTAGAAGAAATTGATCATATT
GGAATTATCTCTTTTCCTGACTTCAAGATTCCGTCTAATCCTAGATATGGTATGTGGACG
ATCAAGGCTAAATATAAAGAGGACTTTTCAACAACTGGAACCGCATATTTTGAAGTTAAA
GAATATGTCTTGCCACATTTTTCTGTCTCAATCGAGCCAGAATATAATTTCATTGGTTAC
AAGAACTTTAAGAATTTTGAAATTACTATAAAAGCAAGATATTTTTATAATAAAGTAGTC
ACTGAGGCTGACGTTTATATCACATTTGGAATAAGAGAAGACTTAAAAGATGATCAAAAA
GAAATGATGCAAACAGCAATGCAAAACACAATGTTGATAAATGGAATTGCTCAAGTCACA
TTTGATTCTGAAACAGCAGTCAAAGAACTGTCATACTACAGTTTAGAAGATTTAAACAAC
AAGTACCTTTATATTGCTGTAACAGTCATAGAGTCTACAGGTGGATTTTCTGAAGAGGCA
GAAATACCTGGCATCAAATATGTCCTCTCTCCCTACAAACTGAATTTGGTTGCTACTCCT
CTTTTCCTGAAGCCTGGGATTCCATATCCCATCAAGGTGCAGGTTAAAGATTCGCTTGAC
CAGTTGGTAGGAGGAGTCCCAGTAACACTGAATGCACAAACAATTGATGTAAACCAAGAG
ACATCTGACTTGGATCCAAGCAAAAGTGTAACACGTGTTGATGATGGAGTAGCTTCCTTT
GTGCTTAATCTCCCATCTGGAGTGACGGTGCTGGAGTTTAATGTCAAAACTGATGCTCCA
GATCTTCCAGAAGAAAATCAGGCCAGGGAAGGTTACCGAGCAATAGCATACTCATCTCTC
AGCCAAAGTTACCTTTATATTGATTGGACTGATAACCATAAGGCTTTGCTAGTGGGAGAA
CATCTGAATATTATTGTTACCCCCAAAAGCCCATATATTGACAAAATAACTCACTATAAT
TACTTGATTTTATCCAAGGGCAAAATTATCCACTTTGGCACGAGGGAGAAATTTTCAGAT
GCATCTTATCAAAGTATAAACATTCCAGTAACACAGAACATGGTTCCTTCATCCCGACTT
CTGGTCTATTACATCGTCACAGGAGAACAGACAGCAGAATTAGTGTCTGATTCAGTCTGG
TTAAATATTGAAGAAAAATGTGGCAACCAGCTCCAGGTTCATCTGTCTCCTGATGCAGAT
GCATATTCTCCAGGCCAAACTGTGTCTCTTAATATGGCAACTGGAATGGATTCCTGGGTG
GCATTAGCAGCAGTGGACAGTGCTGTGTATGGAGTCCAAAGAGGAGCCAAAAAGCCCTTG
GAAAGAGTATTTCAATTCTTAGAGAAGAGTGATCTGGGCTGTGGGGCAGGTGGTGGCCTC
AACAATGCCAATGTGTTCCACCTAGCTGGACTTACCTTCCTCACTAATGCAAATGCAGAT
GACTCCCAAGAAAATGATGAACCTTGTAAAGAAATTCTCAGGCCAAGAAGAACGCTGCAA
AAGAAGATAGAAGAAATAGCTGCTAAATATAAACATTCAGTAGTGAAGAAATGTTGTTAC
GATGGAGCCTGCGTTAATAATGATGAAACCTGTGAGCAGCGAGCTGCACGGATTAGTTTA
GGGCCAAGATGCATCAAAGCTTTCACTGAATGTTGTGTCGTCGCAAGCCAGCTCCGTGCT
AATATCTCTCATAAAGACATGCAATTGGGAAGGCTACACATGAAGACCCTGTTACCAGTA
AGCAAGCCAGAAATTCGGAGTTATTTTCCAGAAAGCTGGTTGTGGGAAGTTCATCTTGTT
CCCAGAAGAAAACAGTTGCAGTTTGCCCTACCTGATTCTCTAACCACCTGGGAAATTCAA
GGCGTTGGCATTTCAAACACTGGTATATGTGTTGCTGATACTGTCAAGGCAAAGGTGTTC
AAAGATGTCTTCCTGGAAATGAATATACCATATTCTGTTGTACGAGGAGAACAGATCCAA
TTGAAAGGAACTGTTTACAACTATAGGACTTCTGGGATGCAGTTCTGTGTTAAAATGTCT
GCTGTGGAGGGAATCTGCACTTCGGAAAGCCCAGTCATTGATCATCAGGGCACAAAGTCC
TCCAAATGTGTGCGCCAGAAAGTAGAGGGCTCCTCCAGTCACTTGGTGACATTCACTGTG
CTTCCTCTGGAAATTGGCCTTCACAACATCAATTTTTCACTGGAGACTTGGTTTGGAAAA
GAAATCTTAGTAAAAACATTACGAGTGGTGCCAGAAGGTGTCAAAAGGGAAAGCTATTCT
GGTGTTACTTTGGATCCTAGGGGTATTTATGGTACCATTAGCAGACGAAAGGAGTTCCCA
TACAGGATACCCTTAGATTTGGTCCCCAAAACAGAAATCAAAAGGATTTTGAGTGTAAAA
GGACTGCTTGTAGGTGAGATCTTGTCTGCAGTTCTAAGTCAGGAAGGCATCAATATCCTA
ACCCACCTCCCCAAAGGGAGTGCAGAGGCGGAGCTGATGAGCGTTGTCCCAGTATTCTAT
GTTTTTCACTACCTGGAAACAGGAAATCATTGGAACATTTTTCATTCTGACCCATTAATT
GAAAAGCAGAAACTGAAGAAAAAATTAAAAGAAGGGATGTTGAGCATTATGTCCTACAGA
AATGCTGACTACTCTTACAGTGTGTGGAAGGGTGGAAGTGCTAGCACTTGGTTAACAGCT
TTTGCTTTAAGAGTACTTGGACAAGTAAATAAATACGTAGAGCAGAACCAAAATTCAATT
TGTAATTCTTTATTGTGGCTAGTTGAGAATTATCAATTAGATAATGGATCTTTCAAGGAA
AATTCACAGTATCAACCAATAAAATTACAGGGTACCTTGCCTGTTGAAGCCCGAGAGAAC
AGCTTATATCTTACAGCCTTTACTGTGATTGGAATTAGAAAGGCTTTCGATATATGCCCC
CTGGTGAAAATCGACACAGCTCTAATTAAAGCTGACAACTTTCTGCTTGAAAATACACTG
CCAGCCCAGAGCACCTTTACATTGGCCATTTCTGCGTATGCTCTTTCCCTGGGAGATAAA
ACTCACCCACAGTTTCGTTCAATTGTTTCAGCTTTGAAGAGAGAAGCTTTGGTTAAAGGT
AATCCACCCATTTATCGTTTTTGGAAAGACAATCTTCAGCATAAAGACAGCTCTGTACCT
AACACTGGTACGGCACGTATGGTAGAAACAACTGCCTATGCTTTACTCACCAGTCTGAAC
TTGAAAGATATAAATTATGTTAACCCAGTCATCAAATGGCTATCAGAAGAGCAGAGGTAT
GGAGGTGGCTTTTATTCAACCCAGGACACAATCAATGCCATTGAGGGCCTGACGGAATAT
TCACTCCTGGTTAAACAACTCCGCTTGAGTATGGACATCGATGTTTCTTACAAGCATAAA
GGTGCCTTACATAATTATAAAATGACAGACAAGAATTTCCTTGGGAGGCCAGTAGAGGTG
CTTCTCAATGATGACCTCATTGTCAGTACAGGATTTGGCAGTGGCTTGGCTACAGTACAT
GTAACAACTGTAGTTCACAAAACCAGTACCTCTGAGGAAGTTTGCAGCTTTTATTTGAAA
ATCGATACTCAGGATATTGAAGCATCCCACTACAGAGGCTACGGAAACTCTGATTACAAA
CGCATAGTAGCATGTGCCAGCTACAAGCCCAGCAGGGAAGAATCATCATCTGGATCCTCT
CATGCGGTGATGGACATCTCCTTGCCTACTGGAATCAGTGCAAATGAAGAAGACTTAAAA
GCCCTTGTGGAAGGGGTGGATCAACTATTCACTGATTACCAAATCAAAGATGGACATGTT
ATTCTGCAACTGAATTCGATTCCCTCCAGTGATTTCCTTTGTGTACGATTCCGGATATTT
GAACTCTTTGAAGTTGGGTTTCTCAGTCCTGCCACTTTCACAGTGTACGAATACCACAGA
CCAGATAAACAGTGTACCATGTTTTATAGCACTTCCAATATCAAAATTCAGAAAGTCTGT
GAAGGAGCCGCGTGCAAGTGTGTAGAAGCTGATTGTGGGCAAATGCAGGAAGAATTGGAT
CTGACAATCTCTGCAGAGACAAGAAAACAAACAGCATGTAAACCAGAGATTGCATATGCT
TATAAAGTTAGCATCACATCCATCACTGTAGAAAATGTTTTTGTCAAGTACAAGGCAACC
CTTCTGGATATCTACAAAACTGGGGAAGCTGTTGCTGAGAAAGACTCTGAGATTACCTTC
ATTAAAAAGGTAACCTGTACTAACGCTGAGCTGGTAAAAGGAAGACAGTACTTAATTATG
GGTAAAGAAGCCCTCCAGATAAAATACAATTTCAGTTTCAGGTACATCTACCCTTTAGAT
TCCTTGACCTGGATTGAATACTGGCCTAGAGACACAACATGTTCATCGTGTCAAGCATTT
TTAGCTAATTTAGATGAATTTGCCGAAGATATCTTTTTAAATGGATGCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00207</identifier>
            <name>A2M</name>
          </pfam>
          <pfam>
            <identifier>PF07678</identifier>
            <name>A2M_comp</name>
          </pfam>
          <pfam>
            <identifier>PF01835</identifier>
            <name>A2M_N</name>
          </pfam>
          <pfam>
            <identifier>PF07703</identifier>
            <name>A2M_N_2</name>
          </pfam>
          <pfam>
            <identifier>PF07677</identifier>
            <name>A2M_recep</name>
          </pfam>
          <pfam>
            <identifier>PF01821</identifier>
            <name>ANATO</name>
          </pfam>
          <pfam>
            <identifier>PF01759</identifier>
            <name>NTR</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane attack complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chemokine activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>endopeptidase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation, alternative pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>complement activation, classical pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitophagy in response to mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of macrophage chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of chemokine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of complement activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to stress</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>